首页 > 市场调查报告书 > 医疗设备

市场调查报告书

商品编码

1594843

全球食物过敏市场 - 2024-2031

Global Food Allergy Market - 2024-2031

出版日期: 2024年11月21日 | 出版商:

DataM Intelligence | 英文 203 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

概述

2023年，全球食物过敏市场规模达到401.6亿美元，预计2031年将达到601.9亿美元，2024-2031年预测期间复合年增长率为5.19%。

世界过敏组织记录了全球食物过敏发生率的上升。鸡蛋、牛奶、小麦、鱼和坚果是最常见的过敏源。值得注意的是，海鲜过敏在亚洲比西方国家更为常见。市场成长与意识的提高、医疗需求的未满足以及新颖产品的推出有关。

先进的诊断技术，如精製血液检测、皮肤点刺测试和分子诊断，透过提高准确性和便利性来促进过敏识别。全球食物过敏诊断和治疗市场展现出良好的发展潜力。这一前景源于对具有成本效益的治疗替代方案的不断增长的需求、诊断技术的发展、肾上腺素自动注射器等新产品的推出以及全球食物过敏发生率的上升。

必须应对药品费用上涨等挑战，以确保市场的持续成长。过敏治疗资金的增加正在推动研究的进步和新药物的供应。 2022年9月，COUR Pharmaceuticals成功完成3,000万美元融资，Alpha Wave Ventures担任主要投资者。

动力学

对无过敏原产品的需求不断增长

全球范围内规避食品和饮料过敏原的人数不断增加（约 5 亿，其中仅美国就有约 8500 万），这表明食物过敏市场存在巨大的成长潜力。在过去的二十年里，美国年轻人食物过敏的发生率与人口成长相比增加了约四倍。这种现像不仅限于美国；有证据表明，全球食物过敏现象呈上升趋势，尤其是已开发国家和发展中国家的幼儿。

麦肯锡公司最近的研究表明，无论是直接受到过敏影响的消费者还是为患有过敏的人购买产品，消费者在穿过杂货店通道以躲避过敏原时经常会遇到压力。许多人投入大量时间分析产品标籤，有些人甚至避开整个产品类别。

此外，这些消费者通常会为优质的、无过敏原的产品支付高价，这表明他们更喜欢较小的、具有过敏意识的公司，而不是较大的同行，同时也在寻求新的产品替代品。在美国，超市无过敏原产品的支出高于平均水平，消费者每年花费近 190 亿美元购买替代品或无过敏原商品。这项支出预计将持续呈上升趋势，凸显食物过敏领域的成长潜力。

人工智慧驱动的创新

由于人们意识的提高，食物过敏产业正在不断扩大，这主要是由人工智慧 (AI) 技术的进步所推动的。人工智慧驱动的解决方案透过准确的产品标籤、成分评估和针对食物过敏者的客製化通知来提高人们的认识。这些进步使个人能够迅速识别物品中的潜在过敏，从而促进安全和明智的决策。

人工智慧驱动的应用程式有助于扫描标籤和分析物质，从而提高过敏原意识，并使个人能够有效管理自己的饮食需求，特别是那些患有严重、多种或罕见过敏且难以找到安全食品替代品的人。除了消费品之外，包括高光谱成像、机器学习、电脑视觉和傅立叶变换红外光谱在内的人工智慧驱动技术也逐渐应用于食品服务和生产中的过敏原检测。

非侵入性技术有利于食品品质评估和污染物识别，从而降低餐厅和加工设施中因交叉接触而发生严重过敏反应的风险。随着人们对食物过敏原的认识不断提高，食品过敏市场有望大幅扩张，消费者和企业都强调安全性和透明度。

诊断和药物费用高

与检测和管理食物过敏（尤其是花生过敏）相关的大量费用对食物过敏行业构成了相当大的限制。研究表明，花生过敏每年会增加每人 304-400 欧元的医疗费用，此外还有 794 欧元的过敏反应治疗费用和 470 欧元的肾上腺素自动注射器 (AAI) 处方费用。对于英国人口来说，每年这些费用总计估计为 4000-5300 万欧元。此类费用可能会限制获得充分诊断和持续治疗的机会，因为个人和医疗机构可能会面临这些额外的财务压力。

价格上涨可能会阻碍预防策略、诊断程序和创新的、可能挽救生命的治疗方法的实施。缺乏足够保险或财务资源的个人可能会忽略过敏测试和管理，增加严重反应的风险。这种限制不仅影响患者，也阻碍食物过敏市场的成长，因为成本上升降低了对复杂诊断设备、治疗和无过敏原产品的可及性和需求，阻碍了市场进步。

The World Allergy Organization has documented a worldwide rise in the incidence of food allergies. Eggs, milk, wheat, fish and tree nuts are among the most prevalent allergies. Notably, seafood allergies are more prevalent in Asia than to Western nations. The market growth is linked to heightened awareness, unfulfilled medical demands and the launch of novel products.

Advanced diagnostic techniques, such as refined blood assays, skin prick tests and molecular diagnostics, promote allergy identification by augmenting precision and expediency. The global market for food allergy diagnostics and therapies exhibits favorable development potential. The prospects arise from the escalating demand for cost-effective treatment alternatives, developments in diagnostic technologies, the introduction of novel products such as epinephrine auto-injectors and the rising incidence of food allergies worldwide.

It is essential to tackle challenges, such as elevated medicine expenses, to guarantee ongoing market growth. The increase in financing for allergy treatments is driving progress in research and the availability of novel medications. In September 2022, COUR Pharmaceuticals successfully concluded a funding round of US$ 30 million, including Alpha Wave Ventures as a principal investor.

Dynamics

Rising Demand for Allergen-Free Products

The global rise in individuals circumventing allergens in food and beverages-approximately 500 million, with roughly 85 million in the US alone-indicates substantial growth potential in the food allergy market. In the last twenty years, the incidence of food allergies in American youths has escalated roughly fourfold compared to population growth. This phenomenon is not limited to US; evidence suggests a global rise in food allergies, especially in young children in both developed and developing countries.

Recent research by McKinsey & Company indicates that consumers, whether directly impacted by allergies or purchasing for someone who is, frequently encounter stress while navigating grocery aisles to evade allergens. Numerous individuals invest significant time analyzing product labels, with some even eschewing entire categories of products.

Moreover, these consumers often pay a premium for superior, allergen-free products, demonstrating a preference for smaller, allergy-aware firms over larger counterparts, while also seeking new product alternatives. In US, spending on allergen-free supermarket products above the average, with consumers allocating nearly US$ 19 billion yearly to alternatives or allergen-free items. This expenditure is expected to persist in its upward trajectory, highlighting the growth potential within the food allergy sector.

AI-Driven Innovations

The food allergy industry is expanding due to heightened awareness, mostly propelled by improvements in artificial intelligence (AI) technology. AI-driven solutions are improving awareness via accurate product labeling, ingredient assessment and tailored notifications for individuals with food allergies. The advancements enable individuals to promptly identify potential allergies in items, facilitating safe and informed decision-making.

AI-powered applications facilitate the scanning of labels and the analysis of substances, thereby enhancing allergen awareness and empowering individuals to effectively manage their dietary requirements-particularly those with severe, multiple or uncommon allergies who have difficulties in locating safe food alternatives. In addition to consumer items, AI-driven technologies including hyperspectral imaging, machine learning, computer vision and Fourier transform infrared spectroscopy are progressively employed in food service and production for allergen detection.

The non-invasive techniques facilitate the assessment of food quality and the identification of pollutants, thereby mitigating the risk of severe allergic reactions due to cross-contact in restaurants and processing facilities. As awareness of food allergens escalates, the food allergy market is poised for substantial expansion, with consumers and businesses alike emphasizing safety and transparency.

High Cost Of Diagnosis And Medication

The substantial expense associated with detecting and managing food allergies, especially peanut allergies, constitutes a considerable limitation on the food allergy industry. Research indicates that peanut allergies contribute an annual incremental healthcare cost of EUR 304-400 per individual, alongside supplementary expenses of EUR 794 for anaphylaxis treatment and EUR 470 for adrenaline auto-injector (AAI) prescriptions. For UK population, these expenses together total an estimated EUR 40-53 million annually. Such fees can restrict access to adequate diagnosis and continuous treatment, as individuals and healthcare institutions may contend with these additional financial pressures.

Rising prices can impede the implementation of preventative strategies, diagnostic procedures and innovative, possibly life-saving treatments. Individuals lacking adequate insurance or financial resources may neglect allergy testing and management, heightening their risk of severe reactions. This constraint affects both patients and hinders the growth of the food allergy market, as elevated costs diminish the accessibility and demand for sophisticated diagnostic equipment, treatments and allergen-free products, hence impeding market progress.

Segment Analysis

The global food allergy market is segmented based on food sources, diagnosis, treatment, distribution channel and region.

High Risk And Treatment Focus For Peanut Allergies

Peanut allergies dominate the food source segment due to the presence of potent allergenic proteins, including Ara h 1, Ara h 2 and Ara h 3, which are known for their ability to trigger severe allergic reactions. These proteins are particularly resilient, resisting both heat and digestion, which increases the likelihood of a reaction even in trace amounts. Peanut allergy is especially dangerous, as it can cause anaphylaxis-a severe, life-threatening allergic response-often with very small exposure to the allergen, making peanuts one of the most high-risk allergens globally.

This dominance is further underscored by the fact that peanut allergy is currently the only food allergy with an FDA-approved treatment, Palforzia, highlighting the seriousness and prevalence of peanut-related reactions. Other treatments, such as peanut oral immunotherapy, are in use to increase tolerance to peanut proteins but remain non-FDA-approved. This specialized treatment focus for peanut allergies, combined with the high-risk profile of peanut proteins, positions peanuts as a leading and particularly challenging subsegment in the food allergy market..

Geographical Penetration

Advancements in North America Diagnosis and Treatment

North America is a developed region characterized by substantial healthcare expenditure. It commands the global market owing to the increasing recognition of potential in allergy therapeutics. Consequently, American corporations are allocating resources to the research and development of anti-allergenic pharmaceuticals. Furthermore, emerging competitors are launching innovative items, resulting in heightened competition among manufacturers.

The significant prevalence of food allergies in US stimulates the need for better diagnosis and effective treatment solutions. US healthcare system is a market leader, recognized for its sophisticated infrastructure, extensive access to medical services and thorough allergy testing and treatments. Advancements in treatment have significantly contributed to market growth and development. Oral immunotherapy presents significant market potential.

Recently, US Food and Drug Administration (FDA) approved Palforzia for the treatment of peanut allergy in children. This oral immunotherapy seeks to mitigate allergic responses, including anaphylaxis, resulting from inadvertent peanut exposure. It is appropriate for children between the ages of four and seventeen who have a verified diagnosis of peanut allergy.

Competitive Landscape

The major global players in the market include Astellas Pharma, Inc., Aimmune Therapeutics, Meridian Medical Technologies, ALK-Abello Ltd, Medeca Pharma AB, bioMeriux SA, Omega Diagnostics Group PLC, HYCOR Biomedical, HOB Biotech Group Corp Ltd. and Cambridge Allergy Ltd.

Russia-Ukraine War Impact Analysis

The Russia-Ukraine conflict has intensified the worldwide food crisis, resulting in heightened awareness and demand for allergy testing as food insecurity amplifies worries regarding the safety of accessible food. Furthermore, logistical obstacles have postponed the distribution of allergy testing kits and associated diagnostic instruments, constraining market expansion in impacted areas.

Conversely, the persistent issue has prompted an escalation in governmental and humanitarian initiatives to bolster healthcare infrastructure in impacted regions, encompassing food allergy detection. Nonetheless, healthcare systems have been overwhelmed and resources are frequently redirected to urgent humanitarian requirements, so impeding the broad availability and accessibility of allergy diagnostic services. This has led to a heterogeneous effect on market expansion, presenting constraints in certain sectors while offering development prospects in others.

Food Source

Dairy Products
Poultry Products
Peanuts
Shellfish
Wheat
Others

Diagnosis

Instruments
Consumables
Services
Tests
- In Vivo/Skin
- In Vitro
Others

Treatment

Epinephrine
Antihistamines
Oral Immunotherapy
Others

Distribution Channel

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

By Region

North America
- US
- Canada
- Mexico
Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe
South America
- Brazil
- Argentina
- Rest of South America
Asia-Pacific
- China
- India
- Japan
- Australia
- Rest of Asia-Pacific
Middle East and Africa

Key Developments

In March 2024, Gold Standard Diagnostics introduced the inaugural product of the new allergy PowerLine tests: the SENSIStrip Gluten PowerLine Lateral Flow Device. The device features a sensitive detection technology utilizing a monoclonal antibody to identify gluten residues in food matrices, rinse water and swabs.
In March 2024, ALS significantly enhanced and fortified its footprint in the Life Sciences sectors of Europe and US. ALS has acquired York Analytical Laboratories, located in Northeast US and Wessling Holding GmbH & Co., based in Western Europe.
In February 2024, Merieux NutriSciences inaugurated a state-of-the-art laboratory for food analysis in Maringa, Brazil. The newly established facility possesses federal CGRE/IMMETRO accreditation in accordance with NBR ISO/IEC 17025 standards, aimed at assisting the food industry in achieving quality benchmarks.

Why Purchase the Report?

To visualize the global food allergy market segmentation based on food source, diagnosis, treatment, distribution channel and region, as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of the food allergy market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as excel consisting of key products of all the major players.

The global food allergy market report would provide approximately 70 tables, 68 figures and 203 pages

Target Audience 2024

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Food Source
3.2. Snippet by Diagnosis
3.3. Snippet by Treatment
3.4. Snippet by Distribution Channel
3.5. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Rising Demand for Allergen-Free Products
  - 4.1.1.2. AI-Driven Innovations
- 4.1.2. Restraints
  - 4.1.2.1. High Cost Of Diagnosis And Medication
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Russia-Ukraine War Impact Analysis
5.6. DMI Opinion

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID-19
- 6.1.2. Scenario During COVID-19
- 6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion

7. By Food Source

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Food Source
- 7.1.2. Market Attractiveness Index, By Food Source
7.2. Dairy Products*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Poultry Products
7.4. Peanuts
7.5. Shellfish
7.6. Wheat
7.7. Others

8. By Diagnosis

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnosis
- 8.1.2. Market Attractiveness Index, By Diagnosis
8.2. Instruments*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Consumables
8.4. Services
8.5. Tests
- 8.5.1. In Vivo/Skin
- 8.5.2. In Vitro
8.6. Others

9. By Treatment

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
- 9.1.2. Market Attractiveness Index, By Treatment
9.2. Epinephrine*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Antihistamines
9.4. Oral Immunotherapy
9.5. Others

10. By Distribution Channel

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 10.1.2. Market Attractiveness Index, By Distribution Channel
10.2. Hospital Pharmacy*
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Retail Pharmacy
10.4. Online Pharmacy

11. By Region

11.1. Introduction
- 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 11.1.2. Market Attractiveness Index, By Region
11.2. North America
- 11.2.1. Introduction
- 11.2.2. Key Region-Specific Dynamics
- 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Food Source
- 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnosis
- 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
- 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.2.7.1. US
  - 11.2.7.2. Canada
  - 11.2.7.3. Mexico
11.3. Europe
- 11.3.1. Introduction
- 11.3.2. Key Region-Specific Dynamics
- 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Food Source
- 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnosis
- 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
- 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.3.7.1. Germany
  - 11.3.7.2. UK
  - 11.3.7.3. France
  - 11.3.7.4. Italy
  - 11.3.7.5. Spain
  - 11.3.7.6. Rest of Europe
11.4. South America
- 11.4.1. Introduction
- 11.4.2. Key Region-Specific Dynamics
- 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Food Source
- 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnosis
- 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
- 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.4.7.1. Brazil
  - 11.4.7.2. Argentina
  - 11.4.7.3. Rest of South America
11.5. Asia-Pacific
- 11.5.1. Introduction
- 11.5.2. Key Region-Specific Dynamics
- 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Food Source
- 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnosis
- 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
- 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.5.7.1. China
  - 11.5.7.2. India
  - 11.5.7.3. Japan
  - 11.5.7.4. Australia
  - 11.5.7.5. Rest of Asia-Pacific
11.6. Middle East and Africa
- 11.6.1. Introduction
- 11.6.2. Key Region-Specific Dynamics
- 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Food Source
- 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnosis
- 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
- 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

12. Competitive Landscape

12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis

13. Company Profiles

13.1. Astellas Pharma, Inc.*
- 13.1.1. Company Overview
- 13.1.2. Product Portfolio and Description
- 13.1.3. Financial Overview
- 13.1.4. Key Developments
13.2. Aimmune Therapeutics
13.3. Meridian Medical Technologies
13.4. ALK-Abello Ltd
13.5. Medeca Pharma AB
13.6. bioMeriux SA
13.7. Omega Diagnostics Group PLC
13.8. HYCOR Biomedical
13.9. HOB Biotech Group Corp Ltd.
13.10. Cambridge Allergy Ltd

LIST NOT EXHAUSTIVE

14. Appendix

14.1. About Us and Services
14.2. Contact Us

02-2729-4219

+886-2-2729-4219

License/价格

全球食物过敏市场 - 2024-2031

Global Food Allergy Market - 2024-2031

目录

第 1 章：方法与范围

第 2 章：定义与概述

第 3 章：执行摘要

第 4 章：动力学

第 5 章：产业分析

第 6 章：COVID-19 分析

第 7 章：依食物来源分类

第 8 章：透过诊断

第 9 章：透过治疗

第 10 章：按配销通路

第 11 章：按地区

第 12 章：竞争格局

第 13 章：公司简介

第 14 章：附录